Personalized vaccines: Unlocking the next era of medical innovation in cancer immunotherapy

Introduction
Precision medicine customizes cancer treatment based on molecular and immune characteristics. Personalized cancer vaccines use genetic analysis of tumors to generate immune responses against unique cancer antigens. Biomarkers—genomic, proteomic, and imaging—combined with AI, guide treatment decisions and predict response.

Cancer Immunotherapy
Tumors evade immunity via "three Cs": camouflage, coercion, and corruption. Key immunotherapies include:

• Checkpoint inhibitors: Anti-CTLA-4, anti-PD-1/PD-L1 antibodies restore T-cell activity but face resistance and immune toxicity.

• Adoptive cell therapies: CAR-T cells succeed in blood cancers but struggle in solid tumors; TCR-T cells target intracellular antigens but risk off-target effects.

• NK cell therapies: Allogeneic CAR-NK cells offer safety advantages but face delivery and persistence challenges.

Vaccines
Vaccines prime adaptive immunity. Therapeutic cancer vaccines target tumor-associated antigens or patient-specific neoantigens. Workflows include biopsy, sequencing, neoantigen prediction, and personalized vaccine production (peptide, RNA, DNA, or dendritic cell-based). Neoantigen vaccines bypass central tolerance, eliciting high-avidity T-cell responses.

mRNA Technology
mRNA platforms enable rapid, scalable production of personalized vaccines encoding multiple neoantigens. Early trials show polyclonal T-cell responses and synergy with checkpoint inhibitors.

Efficacy Barriers and Solutions
Tumors evade vaccines via antigen loss, immunosuppression, and heterogeneity. Practical hurdles include complex manufacturing and cost. Solutions: better neoantigen prediction, faster production, optimized delivery, biomarker-driven selection, and combination therapies.

Clinical Landscape
Four FDA-approved therapeutic cancer vaccines are in use:

• Sipuleucel-T: For metastatic prostate cancer.

• BCG: For early bladder cancer.

• Nadofaragine: Gene therapy for bladder cancer.

• T-VEC: Oncolytic virus for melanoma.
  Recent trials (e.g., KEYNOTE-942) show personalized mRNA vaccines plus pembrolizumab improve outcomes in melanoma and pancreatic cancer.

Ethical and Regulatory Issues
Genomic data use raises privacy concerns; robust governance and equitable access are essential. High costs limit availability, requiring policy solutions.

Future Directions
Advances in sequencing, AI, and delivery systems (lipid nanoparticles) are accelerating vaccine development. Automated, decentralized manufacturing improves scalability and access.

Limitations
Key constraints: fragmented data, small trials, short follow-up, high cost, and global disparities in access.

Conclusions
Precision medicine and immunotherapy have reshaped cancer treatment. While checkpoint inhibitors have revolutionized outcomes for some patients, recent advances in cancer immunotherapy have catalyzed vaccine development as a novel treatment modality, with mRNA-based vaccines offering a personalized and scalable alternative. Therapeutic cancer vaccines, a cornerstone of precision oncology, are designed to elicit targeted immune responses against tumor-specific antigens. These antigens are typically derived from the patient’s own tumor, enabling personalized vaccines that are uniquely tailored to the molecular characteristics of each malignancy. Addressing tumor heterogeneity, optimizing delivery routes, and enhancing immune activation are critical for future success. Integrating mRNA technologies with immune-stimulatory platforms is poised to transform cancer care across multiple indications.

Full text

https://www.xiahepublishing.com/2835-3315/CSP-2025-00023

The study was recently published in the Cancer Screening and Prevention.

Cancer Screening and Prevention (CSP) publishes high-quality research and review articles related to cancer screening and prevention. It aims to provide a platform for studies that develop innovative and creative strategies and precise models for screening, early detection, and prevention of various cancers. Studies on the integration of precision cancer prevention multiomics where cancer screening, early detection and prevention regimens can precisely reflect the risk of cancer from dissected genomic and environmental parameters are particularly welcome.

Follow us on X: @xiahepublishing

Follow us on LinkedIn:  Xia & He Publishing Inc.